One year after the nation learned of the Supreme Court‘s intent to peel back federal protections for abortions via a leaked draft opinion, a new legal fight over the approval of a common abortion drug has ignited condemnation from nearly every corner of the pharmaceutical industry.

Recommended Stories

Justice Department asks Washington court to clarify order maintaining abortion pill

Best part of federal judge’s ruling against abortion pill comes down to two words

Josh Hawley introduces bill to revoke FDA approval of mifepristone for abortions